The dopamine metabolite 3-methoxytyramine is a neuromodulator

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Sotnikova, Tatyana D ^a,b   Beaulieu, Jean Martin ^c   Espinoza, Stefano ^a   Masri, Bernard ^b,d   Zhang, Xiaodong ^e   Salahpour, Ali ^b,f   Barak, Larry S ^b   Caron, Marc G ^b   Gainetdinov, Raul R ^a,b  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^d INSERM   (France)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYLDOPAMINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TAAR1; TRACE AMINE ASSOCIATED RECEPTOR 1 PROTEIN; UNCLASSIFIED DRUG; 3-METHOXYTYRAMINE; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN DISEASE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DYSKINESIA; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HYPERACTIVITY; IN VIVO STUDY; INVOLUNTARY MOVEMENT; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MOUSE MUTANT; PHOSPHORYLATION; WESTERN BLOTTING;

MUS;

ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CORPUS STRIATUM; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DOPAMINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 78149459960     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013452     Document Type: Article

References (64)

1. Molinoff PB, Axelrod J (1971) Biochemistry of catecholamines. Annu Rev Biochem 40: 465-500.
2. Zhou QY, Palmiter RD (1995) Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 83: 1197-1209.
3. Carlsson A (1972) Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl 51: 11-42.
4. Fon EA, Pothos EN, Sun BC, Killeen N, Sulzer D, et al. (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19: 1271-1283.
5. Wang YM, Gainetdinov RR, Fumagalli F, Xu F, Jones SR, et al. (1997) Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19: 1285-1296.
6. Mannisto PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51: 593-628.
7. Westerink BH, Spaan SJ (1982) On the significance of endogenous 3- methoxytyramine for the effects of centrally acting drugs on dopamine release in the rat brain. J Neurochem 38: 680-686.
8. Amara SG, Sonders MS (1998) Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend 51: 87-96.
9. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612.
10. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, et al. (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci U S A 95: 4029-4034.
11. Gainetdinov RR, Caron MG (2003) Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 43: 261-284.
12. Sotnikova TD, Beaulieu JM, Barak LS, Wetsel WC, Caron MG, et al. (2005) Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol 3: e271.
13. Sotnikova TD, Caron MG, Gainetdinov RR (2006) DDD mice, a novel acute mouse model of Parkinson's disease. Neurology 67: S12-S17.
14. Sotnikova TD, Zorina OI, Ghisi V, Caron MG, Gainetdinov RR (2008) Trace amine associated receptor 1 and movement control. Parkinsonism Relat Disord 14 Suppl 2: S99-S102.
15. Borowsky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, et al. (2001) Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A 98: 8966-8971.
16. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, et al. (2001) Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60: 1181-1188.
17. Lindemann L, Hoener MC (2005) A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol Sci 26: 274-281.
18. Grandy DK (2007) Trace amine-associated receptor 1-Family archetype or iconoclast? Pharmacol Ther 116: 355-390.
19. Sotnikova TD, Caron MG, Gainetdinov RR (2009) Trace amine-associated receptors as emerging therapeutic targets. Mol Pharmacol 76: 229-235.
20. Wainscott DB, Little SP, Yin T, Tu Y, Rocco VP, et al. (2007) Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1. J Pharmacol Exp Ther 320: 475-485.
21. Barak LS, Salahpour A, Zhang X, Masri B, Sotnikova TD, et al. (2008) Pharmacological characterization of membrane-expressed human trace amineassociated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol Pharmacol 74: 585-594.
22. Hu LA, Zhou T, Ahn J, Wang S, Zhou J, et al. (2009) Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands. Biochem J 424: 39-45.
23. Osborne RH (1996) Insect neurotransmission: neurotransmitters and their receptors. Pharmacol Ther 69: 117-142.
24. Roeder T (2005) Tyramine and octopamine: ruling behavior and metabolism. Annu Rev Entomol 50: 447-477.
25. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, et al. (2004) Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 101: 5099-5104.
26. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, et al. (1999) Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283: 397-401.
27. Salomon Y, Londos C, Rodbell M (1974) A highly sensitive adenylate cyclase assay. Anal Biochem 58: 541-548.
28. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, et al. (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132: 125-136.
29. Beaulieu JM, Sotnikova TD, Gainetdinov RR, Caron MG (2006) Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J Biol Chem 281: 32072-32080.
30. Girault JA, Valjent E, Caboche J, Herve D (2007) ERK2: a logical AND gate critical for drug-induced plasticity? Curr Opin Pharmacol 7: 77-85.
31. Santini E, Alcacer C, Cacciatore S, Heiman M, Herve D, et al. (2009) L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 108: 621-633.
32. Wolinsky TD, Swanson CJ, Smith KE, Zhong H, Borowsky B, et al. (2006) The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav.
33. Carlsson A, Lindqvist M, Magnusson T, Waldeck B (1958) On the presence of 3- hydroxytyramine in brain. Science 127: 471.
34. Birkmayer W, Hornykiewicz O (1961) [The L-3,4-dioxyphenylalanine (DOPA)- effect in Parkinson-akinesia.]. Wien Klin Wochenschr 73: 787-788.
35. Westerink BH, Spaan SJ (1982) Estimation of the turnover of 3-methoxytyramine in the rat striatum by HPLC with electrochemical detection: implications for the sequence in the cerebral metabolism of dopamine. J Neurochem 38: 342-347.
36. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, et al. (2003) Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab 23: 432-440.
37. Brown EE, Damsma G, Cumming P, Fibiger HC (1991) Interstitial 3-methoxytyramine reflects striatal dopamine release: an in vivo microdialysis study. J Neurochem 57: 701-707.
38. Kehr W (1981) 3-Methoxytyramine and normetanephrine as indicators of dopamine and noradrenaline release in mouse brain in vivo. J Neural Transm 50: 165-178.
39. Vulto AG, Westenberg HG, Meijer LB, Versteeg DH (1986) The dopamine metabolite 3-methoxytyramine is not a suitable indicator of dopamine release in the rat brain. J Neurochem 47: 1387-1393.
40. Elverfors A, Pileblad E, Lagerkvist S, Bergquist F, Jonason J, et al. (1997) 3- Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra. J Neurochem 69: 1684-1692.
41. Baker WW, Zivanovic D, Malseed RT (1976) Tremorogenic effects of intracaudate d-amphetamine and their suppression by dopamine. Arch Int Pharmacodyn Ther 223: 271-281.
42. Jonas W, Scheel-Kruger J (1969) Amphetamine induced stereotyped behaviour correlated with the accumulation of O-methylated dopamine. Arch Int Pharmacodyn Ther 177: 379-389.
43. Nakazato T (2002) The medial prefrontal cortex mediates 3-methoxytyramineinduced behavioural changes in rat. Eur J Pharmacol 442: 73-79.
44. Nakazato T, Akiyama A (2002) Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson's disease. Brain Res 930: 134-142.
45. Charlton CG, Crowell B, Jr. (2000) Effects of dopamine metabolites on locomotor activities and on the binding of dopamine: relevance to the side effects of L-dopa. Life Sci 66: 2159-2171.
46. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
47. Garris PA, Wightman RM (1995) Distinct pharmacological regulation of evoked dopamine efflux in the amygdala and striatum of the rat in vivo. Synapse 20: 269-279.
48. Antkiewicz-Michaluk L, Ossowska K, Romanska I, Michaluk J, Vetulani J (2008) 3-Methoxytyramine, an extraneuronal dopamine metabolite plays a physiological role in the brain as an inhibitory regulator of catecholaminergic activity. Eur J Pharmacol 599: 32-35.
49. Alachkar A, Brotchie JM, Jones OT (2010) Binding of dopamine and 3- methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors. Neurosci Res 67: 245-249.
50. Kato T, Dong B, Ishii K, Kinemuchi H (1986) Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. J Neurochem 46: 1277-1282.
51. Lenders JW, Eisenhofer G, Abeling NG, Berger W, Murphy DL, et al. (1996) Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J Clin Invest 97: 1010-1019.
52. Mannisto PT, Tuomainen P, Tuominen RK (1992) Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br J Pharmacol 105: 569-574.
53. Youdim MB, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7: 295-309.
54. Shih JC, Thompson RF (1999) Monoamine oxidase in neuropsychiatry and behavior. Am J Hum Genet 65: 593-598.
55. D'Souza UM, Craig IW (2008) Functional genetic polymorphisms in serotonin and dopamine gene systems and their significance in behavioural disorders. Prog Brain Res 172: 73-98.
56. Haavik J, Blau N, Thony B (2008) Mutations in human monoamine-related neurotransmitter pathway genes. Hum Mutat 29: 891-902.
57. Gizer IR, Ficks C, Waldman ID (2009) Candidate gene studies of ADHD: a meta-analytic review. Hum Genet 126: 51-90.
58. Diatchenko L, Nackley AG, Slade GD, Bhalang K, Belfer I, et al. (2006) Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 125: 216-224.
59. Apud JA, Weinberger DR (2007) Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. CNS Drugs 21: 535-557.
60. Rajput AH, Fenton ME, Di Paolo T, Sitte H, Pifl C, et al. (2004) Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off. Parkinsonism Relat Disord 10: 221-226.
61. Napolitano A, Zurcher G, Da Prada M (1995) Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur J Pharmacol 273: 215-221.
62. Siirtola T, Sonninen V, Rinne UK (1975) Urinary excretion of monoamines and their metabolites in patients with Parkinson's disease. Response to long-term treatment with levodopa alone or in combination with a dopa decarboxylase inhibitor and clinical correlations. Clin Neurol Neurosurg 78: 77-88.
63. Muskiet FA, Thomasson CG, Gerding AM, Fremouw-Ottevangers DC, Nagel GT, et al. (1979) Determination of catecholamines and their 3-Omethylated metabolites in urine by mass fragmentography with use of deuterated internal standards. Clin Chem 25: 453-460.
64. Dill RE, Campbell KM (1973) 3 methoxytyramine: a possible endogenous toxin of psychosis? Res Commun Chem Pathol Pharmacol 6: 975-982.